CareX and Chemical Diversity Labs announce research agreement
Under the terms of the agreement, Chemical Diversity Labs, Inc. will provide several lead-enriched libraries for CareX's drug discovery targets in the field of metabolic diseases. ICM protein modeling and flexible docking software platform designed by Chemical Diversity's partner MolSoft (San Diego, CA, USA) was used to find potential binders of CareX's targets. Chemical Diversity Labs, Inc. then produced arrays of potential ligands in parallel synthesis and additionally selected likely binding molecules from its world's largest commercial diverse collection of 400,000 small molecules.
Dr. Jurgen Lehmann, CSO of CareX, and Dr. Stanley Lang, VP Chemistry of Chemical Diversity Labs, Inc., were equally excited about the opportunity of joining the possibilities of rational drug design and modern small molecule synthesis with the target knowledge and screening technology of CareX. The new approach of screening a set of maximum diverse compounds as well as several focused libraries on similar targets for an optimized search of the available chemical space for hits was jointly developed by CareX and Chemical Diversity Labs, Inc.
Most read news
Other news from the department business & finance
These products might interest you
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.